{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:06:56Z","timestamp":1777298816196,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ajoc.2022.101440","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T12:14:04Z","timestamp":1645186444000},"page":"101440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Brentuximab vedotin induced uveitis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-0531","authenticated-orcid":false,"given":"Stijn","family":"Therssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stef","family":"Meers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4716-6820","authenticated-orcid":false,"given":"Julie","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8180-3187","authenticated-orcid":false,"given":"Pieter-Paul","family":"Schauwvlieghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajoc.2022.101440_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.ajoc.2022.101440_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"Van der Weyden","year":"2017","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.ajoc.2022.101440_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1634\/theoncologist.2015-0276","volume":"21","author":"Gravanis","year":"2016","journal-title":"Oncol"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101440_bib4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101440_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10792-012-9692-4","article-title":"Indocyanine green angiography-guided management of Vogt\u2013Koyanagi\u2013Harada disease: differentiation between choroidal scars and active lesions","volume":"33","author":"Knecht","year":"2013","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101440_bib6","first-page":"Doc29","article-title":"Brentuximab vedotin related bilateral Purtscher-like retinopathy unresponsive to pulse steroid therapy and intravitreal aflibercept injection","volume":"7","author":"Ayhan","year":"2017","journal-title":"GMS Ophthalmol Cases"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101440_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx091","article-title":"Cytomegalovirus infection with retinitis after brentuximab vedotin treatment for CD30+ lymphoma","volume":"4","author":"Tudesq","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.ajoc.2022.101440_bib8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ajoc.2022.101440_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jcmm.13344","article-title":"Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines","volume":"22","author":"Sch\u00f6nberger","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"21","key":"10.1016\/j.ajoc.2022.101440_bib10","doi-asserted-by":"crossref","first-page":"30523","DOI":"10.18632\/oncotarget.8864","article-title":"CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro","volume":"7","author":"Hansen","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ajoc.2022.101440_bib11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"Muller","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.ajoc.2022.101440_bib12","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41433-019-0693-7","article-title":"Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis","volume":"34","author":"Abu El-Asrar","year":"2020","journal-title":"Eye"},{"issue":"7","key":"10.1016\/j.ajoc.2022.101440_bib13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/10428190290033288","article-title":"Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family","volume":"43","author":"Schneider","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101440_bib14","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0002-9440(10)65018-3","article-title":"Regulation of CD30 antigen expression and its potential significance for human disease","volume":"156","author":"Kadin","year":"2000","journal-title":"Am J Pathol"},{"issue":"18","key":"10.1016\/j.ajoc.2022.101440_bib15","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","article-title":"Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ajoc.2022.101440_bib16","series-title":"Retinal and Choroidal Manifestations of Selected Systemic Diseases","first-page":"539","year":"2013"},{"issue":"1","key":"10.1016\/j.ajoc.2022.101440_bib17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ophtha.2013.09.004","article-title":"Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes","volume":"121","author":"Aronow","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajoc.2022.101440_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/ICU.0b013e328010948d","article-title":"Lymphomas involving the eye and the ocular adnexa","volume":"17","author":"Coupland","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101440_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/09273948.2013.848905","article-title":"Diagnostic procedures in vitreoretinal lymphoma","volume":"22","author":"Dalal","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101440_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622001864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622001864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:04:10Z","timestamp":1762527850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993622001864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":20,"alternative-id":["S2451993622001864"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101440","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brentuximab vedotin induced uveitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101440"}}